All In Biotech

Drug Trial Radar · NCT00060944

A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer

A Randomized, Multicenter, Open-label Study of Yondelis (ET-743 Ecteinascidin) Administered by 2 Different Schedules (Weekly for 3 of 4 Weeks vs. q3 Weeks) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Following Treatment With an Anthracycline and Ifosfamide

Last checked: Nov 19, 2026Latest source record: Sep 8, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 271 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

271

Actual

Start

May 2003

Primary completion

May 2008

Study completion May 2008

Sponsor

Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
Collaborators
PharmaMar
First posted
May 19, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to test the safety and effectiveness of an investigational chemotherapy agent in patients with types of advanced cancer referred to as liposarcoma or leiomyosarcoma.

Conditions

  • Liposarcoma
  • Leiomyosarcoma

Interventions

  • YondelisDrug

    1.5 mg/m2 administered as a 24-hour i.v. infusion on Day 1 of every 21-day treatment cycle.

  • YondelisDrug

    0.58 mg/m2 administered as a 3-hour i.v. infusion on Days 1, 8, and 15 of each 28-day treatment cycle.

  • DexamethasoneDrug

    Pretreatment with 10 mg of dexamethasone i.v. 30 minutes prior to each Yondelis infusion on Days 1, 8, and 15 of each 28-day treatment cycle.

  • DexamethasoneDrug

    Pretreatment with 20 mg of dexamethasone i.v. on Day 1 of each 21- day treatment cycle, 30 minutes prior to each Yondelis infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Progression- Independent ReviewTime frame: From randomization to the first documentation of disease progression or death due to progressive disease, whichever occurs first, assessed up to 5 years

Locations

39 sites in 8 countries. Site status is shown where the registry gives one.

  • Site not named

    Los Angeles, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Coeur d'Alene, Idaho

  • Site not named

    Park Ridge, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Louisville, Kentucky

  • Site not named

    Boston, Massachusetts

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    Rochester, Minnesota

  • Site not named

    Newark, New Jersey

  • Site not named

    New York, New York

  • Site not named

    Cleveland, Ohio

  • Site not named

    Portland, Oregon

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Nashville, Tennessee

  • Site not named

    Houston, Texas

  • Site not named

    Salt Lake City, Utah

  • Site not named

    Seattle, Washington

  • Site not named

    Milwaukee, Wisconsin

  • Site not named

    East Melbourne, Australia

  • Site not named

    Newcastle, Australia

  • Site not named

    Perth, Australia

  • Site not named

    Woodville, Australia

  • Site not named

    Leuven, Belgium

  • Site not named

    Edmonton, Canada

  • Site not named

    Calgary, Alberta, Canada

  • Site not named

    London, Ontario, Canada

  • Site not named

    Ottawa, Ontario, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Lyon, France

  • Site not named

    Villejuif, France

  • Site not named

    Düsseldorf, Germany

  • Site not named

    Moscow, Russia

  • Site not named

    Obninsk, Russia

  • Site not named

    Saint Petersburg, Russia

  • Site not named

    Samara, Russia

  • Site not named

    Barcelona, Spain

  • Site not named

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.